Advancing precision medicine in human epidermal growth factor receptor 2 negative gastric cancer: Insights from a novel nomogram for immunochemotherapy prognosis

doi:10.4251/wjgo.v18.i2.115401

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 2

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (162)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

HTML

Tables (1-1)

Sum=100

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=62

Feb 15, 2026 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastrointest Oncol. Feb 15, 2026; 18(2): 115401
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.115401

Advancing precision medicine in human epidermal growth factor receptor 2 negative gastric cancer: Insights from a novel nomogram for immunochemotherapy prognosis

Abinash Nayak, Gunanidhi Sahoo, Sudhansu Sekhar Nishank

Abinash Nayak, Gunanidhi Sahoo, Sudhansu Sekhar Nishank, Department of Zoology, Utkal University, Bhubaneshwar 751004, Odisha, India

Author contributions: Nayak A performed literature review, collection and drafting of the manuscript; Sahoo G and Nishank SS performed revision of the manuscript. All authors approved the final version to publish.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Corresponding author: Abinash Nayak, MD, Academic Fellow, Assistant Professor, Lecturer, Researcher, Department of Zoology, Utkal University, Vani Vihar, Bhubaneshwar 751004, Odisha, India. abinashnayakzoology@gmail.com

Received: October 17, 2025
Revised: October 24, 2025
Accepted: November 27, 2025
Published online: February 15, 2026
Processing time: 110 Days and 16.9 Hours

Core Tip

Core Tip: The nomogram by Yao et al represents a comprehensive tool for prognosticating outcomes in advanced human epidermal growth factor receptor 2-negative gastric cancer patients on immunochemotherapy. By incorporating immune, clinicopathological, and inflammatory markers, it achieves high discriminative power. Recent advancements in circulatory tumor DNA, artificial intelligence-radiomics, and combination therapies like claudin 18.2-targeting complement this model, highlighting the need for prospective validation to enhance clinical utility.